Apple Health PDL Drug Class Motions
Asthma and COPD Agents

- Anticholinergics
- Phosphodiesterase 4 Inhibitors
- Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- Long Acting Muscarinic Agents
Asthma and COPD Agents

**Recommendation:**

- All products listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Motion: Park
2nd: Schwilke
Asthma and COPD Agents

- Inhaled Corticosteroid Combinations
- Inhaled Corticosteroids
Asthma and COPD Agents

**Recommendation:**
- All products listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Asthma and COPD Agents

Motion: I move that all products in the drug classes listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

▸ Motion: Corsilles
▸ 2nd: Flatebo
Asthma and COPD Agents: Monoclonal Antibodies

**Recommendation:**

- All products in the Asthma and COPD Agents: Monoclonal Antibodies drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Motion: I move that all products in the Asthma and COPD Agents: Monoclonal Antibodies drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Motion: Chawla

2nd: Park
Hematopoietic Agents: Gaucher Disease

**Recommendation:**

- All products in the Hematopoietic Agents: Gaucher Disease drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Motion: I move that all products in the Hematopoietic Agents: Gaucher Disease drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Motion: Buccola

2nd: Schwilke
Hematopoietic Agents : Sickle Cell Anemia

**Recommendation:**

- All products in the Hematopoietic Agents : Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Hematopoietic Agents : Sickle Cell Anemia

**Motion:** I move that all products in the Hematopoietic Agents : Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

**Motion:** MacKay

**2nd:** Beste
Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF)

**Recommendation:**

- All products in the Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Hematopoietic Agents: Granulocyte Colony-Stimulating Factors (G-CSF)

**Motion:** I move that all products in the Hematopoietic Agents: Granulocyte Colony-Stimulating Factors (G-CSF) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

**Motion:** Schwilke

**2nd:** Flatebo
Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS)

**Recommendation:**

- All products in the Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS)

**Motion:** I move that all products in the Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

**Motion:** Park

**2nd:** Corsilles
Immune Modulators: Thalidomide Analogues

**Recommendation:**
- All products in the Immune Modulators: Thalidomide Analogues drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Motion: I move that all products in the Immune Modulators: Thalidomide Analogues drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Motion: Flatebo

2nd: Schwilke
Oncology Agents

- Alkylating Agents – Oral
- Antimetabolites – Oral
- Antineoplastics Misc – Oral
- BCL-2 Inhibitors – Oral
- Histone Deacetylase Inhibitors – Oral
- Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral
- Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral
- Janus Associated Kinase (JAK) Inhibitors – Oral
Oncology Agents

- Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral
- Proteasome Inhibitors – Oral
- XPO1 Inhibitors – Oral
Oncology Agents

**Recommendation:**

- All products listed on slides 20 and 21 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.

- Products in this class may require prior authorization to determine medical necessity.

- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Oncology Agents

Motion: I move that all products in the drug classes listed on slides 20 and 21 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- Motion: Schwilke
- 2nd: Beste
Hematopoietic Agents : Thrombopoiesis (TPO) Stimulating Proteins

**Recommendation:**

- All products in the Hematopoietic Agents : Thrombopoiesis (TPO) Stimulating Proteins drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Hematopoietic Agents : Thrombopoiesis (TPO) Stimulating Proteins

**Motion:** I move that all products in the Hematopoietic Agents : Thrombopoiesis (TPO) Stimulating Proteins drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

**Motion:** Buccola

2nd: Park
Endocrine and Metabolic Agents : Growth Hormone Releasing Hormones (GHRH)

**Recommendation:**

- All products in the Endocrine and Metabolic Agents : Growth Hormone Releasing Hormones (GHRH) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Motion: I move that all products in the Endocrine and Metabolic Agents: Growth Hormone Releasing Hormones (GHRH) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Motion: Corsilles

2nd: Schwilke
Endocrine and Metabolic Agents : Growth Hormones

**Recommendation:**

- All products in the Endocrine and Metabolic Agents : Growth Hormones drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- Products in this class may require prior authorization to determine medical necessity.
- All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
Endocrine and Metabolic Agents: Growth Hormones

**Motion:** I move that all products in the Endocrine and Metabolic Agents: Growth Hormones drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

**Motion: MacKay**

**2nd: Chawla**